Modulation of Neuroinflammation in Poststroke Rehabilitation: The Role of 12/15-Lipoxygenase Inhibition and Baicalein

 WHOM is going to do the EXACT RESEARCH that proves this and CREATES PROTOCOLS? Will your incompetent doctor not step up and ensure this gets done?

Modulation of Neuroinflammation in Poststroke Rehabilitation: The Role of 12/15-Lipoxygenase Inhibition and Baicalein

Amir Tajbakhsh, PhD https://orcid.org/0000-0002-2311-6554, Fatemeh Hosseinpour-Soleimani, PhD student, Mehdi Abedi, PhD https://orcid.org/0000-0002-3405-511X, Mohammad Hashem Hashempur, MD, PhD https://orcid.org/0000-0002-6700-9304 hashempur@gmail.com, and Manica Negahdaripour, PharmD, PhD https://orcid.org/0000-0002-4265-1499 negahdaripour@sums.ac.irAuthor Info & Affiliations

Stroke

New online

https://doi.org/10.1161/STROKEAHA.124.049048

• Abstract
• Graphical Abstract
• Supplemental Material
• References
• eLetters

• Information & Authors
• Metrics & Citations
• Get Access
• References
• Figures

• • Share

Abstract

Neuroinflammation significantly contributes to stroke pathophysiology, leading to tissue damage and neurological deficits. Baicalein, a potent 12/15-LOX (12/15-lipoxygenase) inhibitor, demonstrates neuroprotective effects by reducing inflammatory lipid mediators, modulating key inflammatory pathways, and attenuating oxidative stress. Experimental studies indicate that baicalein can diminish infarct size and neurological deficits while improving safety and tolerability. Combination therapies with baicalein show promise in enhancing stroke outcomes. Overall, targeting 12/15-LOX and employing baicalein represents a promising approach to modulating neuroinflammation and improving recovery in stroke patients. This review highlights the therapeutic potential of inhibiting the 12/15-LOX pathway and utilizing the natural compound baicalein to mitigate poststroke neuroinflammation.

Graphical Abstract